title: One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry.
abstract: OBJECTIVE
  To provide clinical outcome data from everyday practice for the new generation Resolute zotarolimus-eluting stent (R-ZES).
  
  
  RESULTS
  Patients were eligible if placement of ≥1 R-ZES was intended. There were no restrictions on clinical indication, number of treated vessels, and lesion characteristics. The primary endpoint was the adjudicated cumulative 1-year incidence of cardiac death and target vessel myocardial infarction. Twenty-five per cent of the patients were randomly selected for monitoring. We recruited 2,349 patients with 3,147 lesions (1.6±1.0 stents per patient); 46.0% of patients had acute coronary syndrome, 30.5% were diabetic, and ≥1 complex criterion for stent placement was present in 67.5% of patients. One-year follow-up was complete in 97.9% of patients. The 1-year incidence of the primary endpoint was 4.3% (95% CI: 3.5% to 5.2%) and for ARC definite and probable stent thrombosis, 0.9% (0.5% to 1.3%). Clinically driven target lesion revascularisation and target lesion failure were 3.4% (2.7% to 4.3%) and 7.0% (6.0% to 8.2%), respectively. These findings were consistent across all lesion and patient subsets analysed. There were no significant differences in outcomes between monitored and unmonitored patients.
  
  
  CONCLUSIONS
  In everyday practice, the R-ZES performed similarly well as in the RESOLUTE All Comers randomised trial.
authors.affiliation: Heart Center Bad Krozingen, Bad Krozingen, Germany. franz-josef.neumann@herzzentrum.de
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Neumann
authors.forename: Petr
authors.initials: P
authors.lastname: Widimsky
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Belardi
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation / Q000379:methods*; D001118:Argentina; D003324:Coronary Artery Disease / Q000401:mortality* / Q000628:therapy*; D054855:Drug-Eluting Stents; D023381:Endpoint Determination; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007194:India; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology*; D011446:Prospective Studies; D012042:Registries; D020123:Sirolimus / Q000031:analogs & derivatives*; D013019:South Africa; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: C489443:zotarolimus; D020123:Sirolimus